Source comparison
Which Side Effects Resolve Versus Persist
Injection site reactions follow a predictable trajectory that contradicts patient assumptions. Most participants experience localized erythema, mild induration, or transient pruritus during the first 4–8 weeks of therapy. Incidence peaks at 22–25% during month
This comparison does not assign a generated winner or score.
- Injection site reactions follow a predictable trajectory that contradicts patient assumptions. Most participants experience localized erythema, mild induration, or transient pruritus during the first 4–8 weeks of therapy. Incidence peaks at 22–25% during month one, declines to 15–18% by month three, and stabilizes at 12–14% thereafter. The mechanism involves immune recognition of the peptide formulation rather than tissue toxicity: lymphocytic infiltration at injection sites shows no progressive fibrosis or architectural disruption on biopsy samples analyzed in safety substudies. Rotation of injection sites reduces chronic reaction incidence to below 8%.
- Arthralgias. Joint pain affecting predominantly the hands, wrists, and knees. Occur in 8–12% of long-term users but demonstrate a resolution pattern most guides ignore. Pain severity peaks between weeks 8 and 16, corresponds temporally with peak IGF-1 elevation, and declines spontaneously in 60–70% of affected patients by week 24 even with continued therapy. This suggests an adaptive response: initial IGF-1-mediated fluid retention causes transient synovial inflammation, which resolves as extracellular fluid balance normalizes. Patients who develop persistent arthralgias beyond six months typically have pre-existing osteoarthritis or inflammatory joint conditions. Tesamorelin unmasks subclinical pathology rather than creating new disease.
- Carpal tunnel syndrome represents the adverse event requiring the most treatment discontinuations in extended trials. Incidence ranges from 2–4% across studies, onset typically occurs between weeks 12 and 20, and symptoms resolve fully within 4–8 weeks of stopping tesamorelin in 92% of cases. The mechanism involves IGF-1-mediated soft tissue hypertrophy within the carpal tunnel. Increased synovial volume compresses the median nerve. Critically, this effect reverses when IGF-1 normalizes, producing no permanent nerve damage in published case series. Patients with baseline median nerve compression on electrodiagnostic testing face 3–4× higher risk.
- Peripheral edema. Ankle and lower extremity swelling. Affects 5–8% of long-term users and shows minimal progression beyond the first 16 weeks. The underlying mechanism is sodium retention mediated by GH's effects on renal tubular reabsorption. Edema severity correlates with baseline aldosterone levels and responds to low-dose diuretics in refractory cases. Unlike arthralgias, edema rarely resolves spontaneously during continued therapy but disappears within 7–10 days of treatment cessation.